about
HECT and RING finger families of E3 ubiquitin ligases at a glanceCancer metabolism: key players in metabolic reprogrammingComputational and experimental characterization of dVHL establish a Drosophila model of VHL syndromeNeoplasia: Where We Have Been and Where We Are GoingNeoplasia: the second decade.Role of the ubiquitin proteasome system in renal cell carcinoma.VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.Functional significance of erythropoietin in renal cell carcinoma.Phospholipase D: enzymology, functionality, and chemical modulationStructural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro.Oxygen-mediated endocytosis in cancer.Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma.Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic UseA Synthetic Interaction between CDC20 and RAD4 in Saccharomyces cerevisiae upon UV Irradiation.Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death.Neoplasia: An Anniversary of Progress.Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma.Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma
P2860
Q24599672-CE723625-C708-433A-9D6C-8B0226A8F086Q26827663-5FE4DB28-6569-4A18-8077-DD6DF4501DC5Q27336383-4F6193AD-25BE-444F-B632-75B455D7C467Q28395095-54B98486-F0E6-4629-B3CE-4AAA755E1DCAQ30484000-4638997F-CEDD-486E-B095-769FA5A3BB35Q33307879-EB737DB9-277A-4D44-B027-CC5E9881BFF3Q33816341-FEA43BE8-760E-4DFB-9452-0598E7D720DCQ34440418-B6F23A94-B150-4E0D-A2B8-43A93802FB15Q34543726-78404D31-A182-4FAB-8E7E-25310E157DF1Q35599714-769B34DB-DA7F-49A0-81C8-4CD7EF144B10Q36945200-5472CDC0-51BF-4B74-83D4-135A12896E05Q37296289-372399AA-71F1-4993-B45C-ED2CA8E7FAFEQ37571595-E8691B14-ED7F-4528-8F01-B7E0791177E0Q37611238-72B503AF-E663-46CE-A579-8700E205ED0BQ38269007-7E6BEC1E-B9F0-4171-8040-E520AAFC0E5EQ39926383-01879C41-B2F3-4A73-8312-5AECCC524A44Q40052813-DD434769-E593-428F-B862-D6B078168447Q41765603-4319DF5B-A913-42B9-86E1-0E07198EEF6FQ46932476-EB4BB802-E947-4BBC-9137-B5E5C9549F51Q47431249-1780B795-0F96-45C3-9274-8E82660CA91BQ58585040-D881A87D-0A6A-45FC-BAA6-CBE683715482
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Ubiquitin pathway in VHL cancer syndrome.
@ast
Ubiquitin pathway in VHL cancer syndrome.
@en
type
label
Ubiquitin pathway in VHL cancer syndrome.
@ast
Ubiquitin pathway in VHL cancer syndrome.
@en
prefLabel
Ubiquitin pathway in VHL cancer syndrome.
@ast
Ubiquitin pathway in VHL cancer syndrome.
@en
P2860
P356
P1433
P1476
Ubiquitin pathway in VHL cancer syndrome.
@en
P2093
Michael Ohh
P2860
P304
P356
10.1593/NEO.06442
P577
2006-08-01T00:00:00Z